Smith & Nephew SNATS's (SNN) Market Perform Rating Reaffirmed at Sanford C. Bernstein

Key Points

• Smith & Nephew SNATS's stock received a "market perform" rating from Sanford C. Bernstein, with a target price set at $37.50, indicating a potential upside of 6.32% from its last close.
• A consensus rating of "Hold" has emerged among analysts for Smith & Nephew SNATS, with an average price target of $36.75.
• Institutional ownership of Smith & Nephew SNATS stands at 25.64%, with significant recent stake increases from several large investors.

Smith & Nephew SNATS (NYSE:SNN - Get Free Report)'s stock had its "market perform" rating reiterated by analysts at Sanford C. Bernstein in a research note issued on Tuesday, Marketbeat.com reports. They presently have a $37.50 target price on the medical equipment provider's stock. Sanford C. Bernstein's target price would indicate a potential upside of 6.32% from the company's previous close.

A number of other equities analysts have also issued reports on SNN. Weiss Ratings reissued a "hold (c+)" rating on shares of Smith & Nephew SNATS in a report on Wednesday, October 8th. Wall Street Zen lowered Smith & Nephew SNATS from a "strong-buy" rating to a "buy" rating in a report on Friday, October 3rd. Finally, Canaccord Genuity Group lifted their price target on Smith & Nephew SNATS from $28.00 to $36.00 and gave the company a "hold" rating in a research report on Monday, August 18th. Eight research analysts have rated the stock with a Hold rating, According to MarketBeat, Smith & Nephew SNATS has a consensus rating of "Hold" and a consensus price target of $36.75.

Smith & Nephew SNATS Stock Performance

Shares of SNN stock opened at $35.27 on Tuesday. Smith & Nephew SNATS has a 12-month low of $23.69 and a 12-month high of $38.79. The firm has a market capitalization of $15.05 billion, a price-to-earnings ratio of 16.33, a price-to-earnings-growth ratio of 0.97 and a beta of 0.69. The business has a 50 day simple moving average of $36.71 and a 200 day simple moving average of $31.57. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40.

Institutional Investors Weigh In On Smith & Nephew SNATS

Large investors have recently modified their holdings of the stock. Hexagon Capital Partners LLC boosted its stake in shares of Smith & Nephew SNATS by 63.3% during the 1st quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider's stock worth $30,000 after acquiring an additional 406 shares in the last quarter. Richards Merrill & Peterson Inc. lifted its holdings in shares of Smith & Nephew SNATS by 500.0% in the first quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider's stock valued at $34,000 after purchasing an additional 1,000 shares in the last quarter. AlphaCore Capital LLC purchased a new stake in shares of Smith & Nephew SNATS in the second quarter valued at $44,000. Bessemer Group Inc. lifted its holdings in shares of Smith & Nephew SNATS by 3,471.4% in the first quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock valued at $49,000 after purchasing an additional 1,701 shares in the last quarter. Finally, Banque Transatlantique SA purchased a new stake in shares of Smith & Nephew SNATS in the first quarter valued at $52,000. 25.64% of the stock is owned by institutional investors.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.